A Randomized, Placebo Controlled, Double-Blind, Third Party Open, Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Female Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2015
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Pfizer
- 20 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jan 2013 Planned End Date changed from 1 Feb 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 11 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.